Esperion Therapeutics, Inc.
NASDAQ:ESPR · NASDAQ Global Market
+$0.00 today
Vol 17.00M · Avg 12.29M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
7.5%
avg -13.3%
ROIC
10.9%
avg -72.6%
ROA
-4.9%
avg -56.4%
Analysis
ROIC is currently the strongest return metric at 10.9% versus its period average of -72.6%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Sheldon L. Koenig | President, Chief Executive Officer & Director | $1.43M | — | 60 | $2.17M | 1.05% |
Benjamin Halladay | Chief Financial Officer | $755,083.00 | — | 40 | $679,348.00 | 0.33% |
Benjamin O. Looker | Chief Legal and Corporate Affairs Officer | $696,350.00 | — | 44 | $679,348.00 | 0.33% |
John Harlow | Chief Commercial Officer | $582,940.00 | — | 50 | $79,873.00 | 0.04% |
Tiffany Aldrich | Associate Director of Corporate Communications | — | — | — | — | — |
Glenn Brame | Chief Technical Operations Officer | — | — | 69 | — | — |
Stephen Pinkosky | Vice President of Drug Discovery of Early Pre-Clinical Development | — | — | — | $69,261.00 | 0.03% |
Betty Jean Swartz | Chief Business Officer | — | — | — | — | — |
LeAnne Bloedon | Vice President & Head of Development | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
12
$453,316.94
Net Sentiment
$453,316.94
Net selling
Most Active
Looker Benjamin
5 transactions
1–10 of 12
Analysis
Insiders reported 0 buys worth $0.00 and 12 sells worth $453,316.94 over the last 12 months. That adds up to net selling of $453,316.94. Looker Benjamin was the most active insider with 5 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | N/A3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Absci Corporation
NASDAQ:ABSI
$1.14B
Ventyx Biosciences, Inc.
VTYX
$1.00B
Corvus Pharmaceuticals, Inc.
NASDAQ:CRVS
$991.47M
Olema Pharmaceuticals, Inc.
NASDAQ:OLMA
$801.41M
Aquestive Therapeutics, Inc.
NASDAQ:AQST
$462.58M
REGENXBIO Inc.
NASDAQ:RGNX
$417.20M
Emergent BioSolutions Inc.
NYSE:EBS
$411.48M
Orthofix Medical Inc.
NASDAQ:OFIX
$373.16M
SNDL Inc.
NASDAQ:SNDL
$368.17M
SIGA Technologies, Inc.
NASDAQ:SIGA
$308.05M
Who manages ESPR?
Esperion Therapeutics, Inc. (ESPR) lists 9 active executives. The top listed executive is Tiffany Aldrich, Associate Director of Corporate Communications.
Are ESPR insiders buying or selling?
Recent insider activity shows net buying of $14.75M.
Explore More
Continue the stock analysis
Jump to another research area for this company.